Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) – Equities research analysts at Jefferies Group issued their Q1 2018 earnings per share estimates for Dova Pharmaceuticals in a note issued to investors on Thursday. Jefferies Group analyst E. Yang expects that the company will post earnings per share of ($0.42) for the quarter. Jefferies Group has a “Buy” rating and a $30.00 price target on the stock. Jefferies Group also issued estimates for Dova Pharmaceuticals’ Q2 2018 earnings at ($0.45) EPS, Q3 2018 earnings at ($0.46) EPS and Q4 2018 earnings at ($0.53) EPS.
A number of other analysts have also recently commented on the company. Leerink Swann initiated coverage on Dova Pharmaceuticals in a research report on Monday, July 24th. They issued a “market perform” rating and a $24.00 price target on the stock. J P Morgan Chase & Co initiated coverage on Dova Pharmaceuticals in a research report on Monday, July 24th. They issued an “overweight” rating and a $35.00 price target on the stock. Finally, Zacks Investment Research raised Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price target on the stock in a research report on Wednesday, October 11th.
TRADEMARK VIOLATION WARNING: “Analysts Set Expectations for Dova Pharmaceuticals, Inc.’s Q1 2018 Earnings (DOVA)” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/11/14/analysts-set-expectations-for-dova-pharmaceuticals-inc-s-q1-2018-earnings-dova.html.
Shares of Dova Pharmaceuticals (NASDAQ DOVA) opened at $24.92 on Monday. Dova Pharmaceuticals has a 12-month low of $16.98 and a 12-month high of $29.99.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.08). During the same period in the previous year, the company earned ($0.41) earnings per share.
A number of hedge funds and other institutional investors have recently made changes to their positions in DOVA. FMR LLC purchased a new position in Dova Pharmaceuticals in the 2nd quarter worth approximately $43,969,000. Fosun International Ltd purchased a new position in Dova Pharmaceuticals in the 2nd quarter worth approximately $14,489,000. Paulson & CO. Inc. purchased a new position in Dova Pharmaceuticals in the 2nd quarter worth approximately $13,856,000. Wells Fargo & Company MN purchased a new position in Dova Pharmaceuticals in the 2nd quarter worth approximately $4,458,000. Finally, Nexthera Capital LP purchased a new position in Dova Pharmaceuticals in the 2nd quarter worth approximately $4,415,000. Institutional investors own 23.67% of the company’s stock.
In related news, Director Paul B. Manning purchased 25,870 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were purchased at an average cost of $22.30 per share, with a total value of $576,901.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.